The institutional sentiment increased to 4 in Q2 2015. Its up 2.40, from 1.6 in 2015Q1. The ratio improved, as 5 funds sold all Recro Pharma Inc shares owned while 0 reduced positions. 13 funds bought stakes while 7 increased positions. They now own 5.11 million shares or 98.28% more from 2.57 million shares in 2015Q1.

Cormorant Asset Management Llc holds 1.34% of its portfolio in Recro Pharma Inc for 780,000 shares. Broadfin Capital Llc owns 1.41 million shares or 0.98% of their US portfolio. Moreover, Bogle Investment Management L P De has 0.03% invested in the company for 30,929 shares. The New York-based Spark Investment Management Llc has invested 0.03% in the stock. Bb&T Corp, a North Carolina-based fund reported 50,800 shares.

Recro Pharma, Inc. is a clinical-stage specialty pharmaceutical company. The company has a market cap of $55.04 million. The Firm is engaged in developing non-opioid therapeutics for the treatment of pain, initially for acute pain following surgery. It currently has negative earnings. The Company’s lead product is an intranasal formulation of Dexmedetomidine .

The post Earnings Per Share for Recro Pharma Inc (REPH) Projected to Decrease appeared first on Octafinance.